Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Relapsed or Refractory DLBCL
NCT01278615Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Dec 2010; status: terminated.
02
Drugs
selumetinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01278615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01278615.